

# Druggable causal genes of bipolar disorder identified through Mendelian Randomization analysis offer a route to intervention in integrated stress response

1 **Zhai Ting**<sup>1,2\*</sup>

2 <sup>1</sup> School of Humanities, Southeast University, Nanjing, 211189, China

3 <sup>2</sup>Key Laboratory of Child Development and Learning Science (Southeast University), Ministry of  
4 Education, and Institute of Child Development and Education, Southeast University, Nanjing  
5 210096, China

6 \* **Correspondence:**

7 Zhai Ting

8 [matthewzhai@foxmail.com](mailto:matthewzhai@foxmail.com)

9 **Keywords: bipolar disorder, integrated stress response, summary data-based Mendelian**  
10 **randomization, genome-wide association study (GWAS), colocalization analysis.**

## 11 **Abstract**

12 Bipolar disorder (BD) is known to be comorbid with many medical and psychiatric conditions and  
13 they may share inflammatory and stress-related aetiologies, which could give rise to this association.  
14 Psychosomatic illnesses are characterized by widespread immune signaling in the central nervous  
15 system, oxidative stress, and increased immune trafficking into the brain. The integrated stress  
16 response (ISR) responds to a variety of different stress conditions that lead to alterations in cellular  
17 homeostasis. However, as a causative mechanism underlying the cognitive deficits and  
18 neurodegeneration in a broad range of brain disorders, the impact of ISR on BD is understudied,  
19 particularly for the ISR's central regulatory switch lies in eIF2 ternary complex formation. We aimed  
20 to prioritize eIF2-associated genes for follow-up studies using the summary data-based Mendelian  
21 Randomization (SMR) and Bayesian colocalization (COLOC) methods to integrate the summary-  
22 level data of the GWAS on BD and the expression quantitative trait locus (eQTL) study in blood. We  
23 utilized the GWAS data including 41917 BD cases and 371549 controls from the Psychiatric  
24 Genomics Consortium and the eQTL data from 31,684 participants of predominantly European  
25 ancestry from the eQTLGen consortium. Plus, we use Graph DB to alt drug targets. The SMR  
26 analysis identified EIF2B5 gene that were associated with BD due to no linkage but pleiotropy or  
27 causality. The COLOC analysis strongly suggested that EIF2B5 and the trait of BD were affected by  
28 shared causal variants, and thus were colocalized. Utilizing data in EpiGraphDB we find other  
29 putative causal BD genes (EIF2AK4 and GSK3B) to prioritise potential alternative drug targets.

## 30 **1 Introduction**

31 Bipolar disorders (In this article, the abbreviation BD will be used to refer to Bipolar disorders) are  
32 described by the *Diagnostic and statistical manual of mental disorders: DSM-5™, 5th ed* (2013) as a  
33 group of brain disorders that cause extreme fluctuation in a person's mood, energy, and ability to  
34 function. People who live with bipolar disorder experience periods of great excitement, overactivity,  
35 delusions, and euphoria (known as mania) and other periods of feeling sad and hopeless (known as  
36 depression). The prevalence of bipolar disorders was consistent across diverse cultures and ethnic

37 groups, with an aggregate lifetime prevalence of 0.6% for bipolar I disorder, 0.4% for bipolar II  
38 disorder, 1.4% for subthreshold bipolar disorder, and 2.4% for the bipolar disorder spectrum(Grande  
39 et al., 2016). A better understanding of the underlying pathophysiology may aid in improving  
40 diagnostic accuracy and patient treatment stratification(Vieta et al., 2018); however, the  
41 pathophysiology mechanism of BD remains unclear.

42 As noted by Rowland and Marwaha (2018), while numerous genetic and environmental risk factors  
43 have been identified, the attributable risk of individual factors is often small, and most are not  
44 specific to bipolar disorder but are associated with several mental illnesses. This is evident in the case  
45 of several studies, which have postulated a convergence between BD and medical comorbidities and  
46 may point towards shared inflammatory pathophysiology of the disorders(Leboyer et al., 2012;  
47 Rosenblat & McIntyre, 2015).

48 Thus far, a number of studies have revealed a correlation between BD and diverse stress inputs—  
49 including proteostasis defects(Mayer et al., 2018), nutrient deprivation(Zhuang et al., 2009), viral  
50 infection(Prusty et al., 2018), and redox imbalance(Gu et al., 2015; Kulak et al., 2013; Lackovic et  
51 al., 2013). All of these will lead to the reduction in general translation initiation rates and the increase  
52 in translation of specific messenger RNAs. These two processes reprogram gene expression to  
53 maintain cellular equilibrium, sustain protein-folding capacity, support differentiation, and respond to  
54 injury. When the stress cannot be mitigated, the integrated stress response (ISR) triggers apoptosis to  
55 eliminate the damaged cell.

56 The ISR is an evolutionarily conserved intracellular signaling network that helps the cell, tissue, and  
57 organism to adapt to a variable environment and maintain health. In response to different  
58 environmental and pathological conditions, including protein homeostasis (proteostasis) defects,  
59 nutrient deprivation, viral infection, and oxidative stress, the ISR restores balance by reprogramming  
60 gene expression. The various stresses are sensed by four specialized kinases (PERK, GCN2, PKR  
61 and HRI) that converge on phosphorylation of a single serine on the eukaryotic translation initiation  
62 factor eIF2. eIF2 phosphorylation blocks the action of eIF2's guanine nucleotide exchange factor  
63 termed eIF2B, resulting in a general reduction in protein synthesis. However, if the stress cannot be  
64 mitigated, the ISR triggers apoptosis to eliminate the damaged cell(Costa-Mattioli & Walter, 2020).  
65 Extensive research has shown that the ISR is activated in a wide range of disorders of the brain. This  
66 activation is evidenced by detection of eIF2-P and phosphorylation of PKR, PERK, and GCN2 in  
67 post-mortem brains from individuals and animal models of cognitive and neurodegenerative  
68 disorders, including Alzheimer's disease, Parkinson's disease, Huntington disease, amyotrophic  
69 lateral sclerosis (ALS), traumatic brain injury, Down syndrome, and Charcot-Marie-Tooth disease  
70 (Atkin et al., 2008; Buffington et al., 2014; Chang et al., 2002; Hoozemans et al., 2007; Ishimura et  
71 al., 2016; Moon et al., 2018; Smith & Mallucci, 2016). Notably, ISR activation causes cognitive  
72 defects in mouse models of traumatic brain injury (Chou et al., 2017; Sen et al., 2017), and  
73 Alzheimer's disease (Hwang et al., 2017; Tible et al., 2019). Whilst increasing data highlight that  
74 highly debilitating stress comorbidities such as depression, anxiety disorders, PTSD and epilepsy  
75 share pathogenic mechanisms with stress dysfunction and between each other. These mechanisms are  
76 probably deeply connected and the structural and functional change caused by one disease triggers  
77 the other, despite these it is still not clear on the relationship between them(de Kloet, Joëls, &  
78 Holsboer, 2005; de Kloet, Sibug, et al., 2005; Gold et al., 1988; Kanner, 2012).

79 However, in response to diverse stress stimuli, eukaryotic cells activate a common adaptive pathway,  
80 termed the ISR, to restore cellular homeostasis. So, there's an obvious question, research to date has  
81 not yet determined if ISR would bring patients mood disorder, the evidence for this relationship is


82 inconclusive. Considering the negative impacts that multimorbidity of BD can have on people's life,  
83 identifying this multimorbidity patterns can help provide clues to disease prevention and treatment  
84 and improve prognosis.

85 The approach to empirical research adopted for this study was Mendelian Randomization(MR)  
86 analysis, which is a reliable method to determine causal effects between risk factors and outcomes  
87 using genetic data, which can effectively eliminate the interference of confounding factors (Emdin et  
88 al., 2017). In addition, colocalization is an essential analytical method for exploring the common  
89 causal molecular mechanism among different diseases and disease-related intermediate phenotypes  
90 (Wu et al., 2019). The specific objective of this study was to describe the association between ISR  
91 and BD. As a result, we prioritized several eIF2-associated genes for follow-up functional studies in  
92 future to elucidate the underlying disease mechanisms. we systematically applied summary data-  
93 based Mendelian randomization analysis (SMR) and colocalization (COLOC) to prioritize putative  
94 causal genes using publicly available eQTL datasets. Furthermore, we try to explore potential  
95 alternative drug targets by searching candidate genes available from EpiGraphDB. Then, using MR  
96 analysis to enhance our confidence in identifying potential viable drug targets.

## 97 2 Methods

### 98 2.1 Study design and data resources

99 Figure 1 describes the design of this study.



100

101

Figure 1 Study overview.

102 For the summary-level data of the GWAS on BD, we used summary statistics of 41917 BD cases and  
103 371549 controls from the Psychiatric Genomics Consortium (Sullivan, 2023). Tissue cis-QTL data  
104 were from the Genotype-Tissue Expression (GTEx) project (Consortium et al., 2020). We  
105 downloaded lite version of the GTEx V8 eqtl data (only SNPs with  $P < 1e-5$  are included). This is a  
106 set of cis-eQTL summary data across 49 human tissues from the GTEx project. Only SNPs within  
107 1Mb of the transcription start site are available. Blood eQTL summary statistics of eIF2 genes were  
108 obtained from eQTLGen including the genetic data of blood gene expression in 31,684 individuals  
109 derived from 37 datasets (Vösa et al., 2021).

## 110 **2.2 SMR analysis**

111 We conducted SMR and heterogeneity in dependent instruments (HEIDI) tests in cis regions using  
112 the SMR software tool version 1.3.1. Detailed methods for SMR analysis were described in the  
113 original SMR paper (Zhu et al., 2016). The SMR software tool was originally developed to  
114 implement the SMR & HEIDI methods to test for pleiotropic association between the expression  
115 level of a gene and a complex trait of interest using summary-level data from GWAS and expression  
116 quantitative trait loci (eQTL) studies. The SMR & HEIDI methodology can be interpreted as an  
117 analysis to test if the effect size of a SNP on the phenotype is mediated by gene expression. This tool  
118 can therefore be used to prioritize genes underlying GWAS hits for follow-up functional studies.

119 The default p-value threshold to select the top associated eQTL for the SMR test is  $5.0e-8$ . By  
120 default, we only run the SMR analysis in the cis regions. The default threshold of eQTL p-value to  
121 select eQTLs for the HEIDI test is  $1.57e-3$ , which is equivalent to a chi-squared value ( $df=1$ ) of 10.  
122 The window centred around the probe to select cis-eQTLs (passing a p-value threshold) for the SMR  
123 analysis is 2000Kb.

## 124 **2.3 COLOC analysis**

125 We conducted COLOC analysis using the coloc package (Giambartolomei et al., 2014) in R software  
126 (version 4.3.2). The coloc package can be used to perform genetic colocalisation analysis of two  
127 potentially related phenotypes, to ask whether they share common genetic causal variant(s) in a given  
128 region. This package(version 5) supercedes previously published version 4 by introducing use of the  
129 SuSiE approach to deal with multiple causal variants rather than conditioning or masking(Wang et  
130 al., 2020).

131 COLOC analysis calculates posterior probabilities (PPs) of the five hypotheses: 1) H0; no association  
132 with either gene expression or phenotype; 2) H1; association with gene expression, not with the  
133 phenotype; 3) H2; association with the phenotype, not with gene expression; 4) H3; association with  
134 gene expression and phenotype by independent SNVs; and 5) H4; association with gene expression  
135 and phenotype by shared causal SNVs. A large PP for H4 (PP.H4 above 0.95) strongly supports  
136 shared causal variants affecting both gene expression and phenotype.

## 137 **2.4 PPI networks & Mendelian randomization**

138 Systematic MR of molecular phenotypes such as proteins and expression of transcript levels offer  
139 enormous potential to prioritise drug targets for further investigation. However, many genes and gene  
140 products are not easily druggable, so some potentially important causal genes may not offer an  
141 obvious route to intervention.

142 A parallel problem is that current GWASes of molecular phenotypes have limited sample sizes and  
143 limited protein coverages. A potential way to address both these problems is to use protein-protein  
144 interaction information to identify druggable targets which are linked to a non-druggable, but  
145 robustly causal target. Their relationship to the causal target increases our confidence in their  
146 potential causal role even if the initial evidence of effect is below our multiple-testing threshold.

147 Here, we use data in EpiGraphDB to prioritise potential alternative drug targets in the same PPI  
148 network, as follows:

149 For an existing drug target of interests, we use PPI networks to search for its directly interacting  
150 genes that are evidenced to be druggable.(Liu et al., 2020). We then examine the causal evidence of  
151 these candidate genes on the disease by using two-sample Mendelian randomization (MR) (Hemani  
152 et al., 2018).

### 153 **3 Results**

#### 154 **3.1 SMR and COLOC analyses using blood eQTL datas**

155 The overall results are presented in Table 1.

Table 1 SMR/HEIDI results using the GWAS data on BD.

ProbID	PROBECHR	GENE	TOPSNP	TOPSNP_CHR	A1	A2	FREQ	B_GWAS	SE_GWAS	P_GWAS	B_EQT	SE_EQT	P_EQT	B_SMR	SE_SMR	P_SMR	P_HEIDI	NSNP_HEIDI	FDR
ENSG00000070785	1	EHF2B3	rs399628	1	A	C	0.375746	-1.0029	0.0095	0.7613	0.143125	0.0200113	8.5382E-13	-7.00716	0.981964	9.6179E-13	3.708E-10	16	1.1541E-12
ENSG00000143486	1	EHF2D	rs6692859	1	G	A	0.425447	0.99541	0.0095	0.6305	0.252463	0.0246545	1.3118E-24	3.9428	0.386871	2.1642E-24	2.8087E-25	16	5.1941E-24
ENSG00000055332	2	EHF2AK2	rs4648160	2	T	C	0.0427435	-0.97356	0.022	0.2236	-0.492181	0.0593344	1.0855E-16	1.97805	0.242615	3.5488E-16	3.6422E-15	20	6.0836E-16
ENSG00000172071	2	EHF2AK3	rs10203616	2	C	T	0.0636183	-1.02798	0.0176	0.1165	0.380813	0.0658245	7.2394E-09	-2.69944	0.468888	8.557E-09	4.0199E-13	7	9.2539E-09
ENSG00000144895	3	EHF2A	rs2868946	3	C	T	0.856859	-1.0008	0.013	0.9495	0.682109	0.0346387	2.5199E-86	-1.46721	0.0769066	3.8571E-81	2.9752E-14	20	4.6286E-80
ENSG00000145191	3	EHF2B5	rs843360	3	A	T	0.442346	-1.01217	0.0094	0.1974	0.117791	0.0204781	8.8164E-09	-8.59293	1.49602	9.2539E-09	0.3175938	8	9.2539E-09
ENSG00000086232	7	EHF2AK1	rs4724770	7	G	A	0.828032	-0.97404	0.0119	0.02699	-0.24618	0.0270822	9.8949E-20	3.95662	0.437943	1.6467E-19	8.539E-55	20	3.2934E-19
ENSG00000236493	10	EHF2S2P3	rs11187107	10	A	G	0.361829	-1.00854	0.0098	0.3851	0.341224	0.0424696	9.3928E-16	-2.95565	0.368988	1.1455E-15	4.0277E-13	20	1.7183E-15
ENSG00000111361	12	EHF2B1	rs112286578	12	A	C	0.163022	-0.99015	0.0129	0.4399	0.331611	0.0314287	5.0136E-26	-2.98588	0.28865	1.4206E-25	2.1631E-17	20	4.2619E-25
ENSG00000134001	14	EHF2S1	rs12590956	14	G	A	0.0715706	-1.04227	0.0195	0.03332	-0.190429	0.0240201	2.2285E-15	5.47327	0.697933	4.43E-15	0.0008309	20	5.9066E-15
ENSG00000119718	14	EHF2B2	rs175040	14	G	A	0.461233	-1.00361	0.0093	0.6958	-0.500686	0.0324789	1.2834E-53	2.00447	0.131348	1.3954E-52	1.9281E-31	20	8.3726E-52
ENSG00000128829	15	EHF2AK4	rs7271415	15	G	A	0.333002	-0.98857	0.0099	0.2496	0.36058	0.0289515	1.3195E-35	-2.74161	0.221833	4.3623E-35	1.0534E-25	20	1.7449E-34

It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/) .



157 Since the ISR’s central regulatory switch lies in eIF2 ternary complex formation, we chose eIF2-  
158 related genes as exposure.

159 First, we conducted the SMR analysis to integrate the GWAS and blood eQTL data to identify the  
160 most relevant genes whose expression in blood was significantly associated with the trait of BD.  
161 Only one gene passed the SMR test. In chromosome 3, EIF2B5 gene passed both the SMR and  
162 HEIDI tests and thus were significantly associated with the trait of BD because of pleiotropy or  
163 causality.

164 Next, we conducted the COLOC analysis to integrate the GWAS and blood eQTL data of the genes  
165 that passed the SMR test and assess whether the genes were colocalized with the trait of BD. It can  
166 be seen from the data in Table 2 that there is strong support for colocalization between the trait and  
167 the EIF2B5 gene that passed both SMR and HEIDI tests.

168 Table 2 COLOC results of the genes that passed the SMR test

snp	pvalue	MAF	N.d	V.df	z.dfl	r.dfl	lABF.	pvalue	MAF	N.d	V.df2	z.df2	r.df2	lABF.	internal.su	SNP.P
	s.dfl	.df1	fl	1			df1	s.df2	.df2	f2				df2	m.lABF	P.H4
rs843	0.1974	0.510	500	0.000	1.288	0.9954	-	4.2643	0.510	100	0.0002	10.348	0.9911	50.704	48.830665	1
360		834	00	181	9945	9542	1.8743	E-25	834	00	0009	1992	8533	9839		
							189									

## 169 3.2 Alt Drug Target

### 170 3.2.1 Using PPI networks for alternative drug targets search

171 The assumption here is that the most likely alternative targets are either directly interacting with  
172 EIF2B5 or somewhere in the same PPI network. In this example, we consider only genes that were  
173 found to interact with EIF2B5 via direct protein-protein interactions, and require that those  
174 interacting proteins should also be druggable.

175 The thousands of genes are classified with regard to their druggability by (Finan et al., 2017), where  
176 the Tier 1 category refers to approved drugs or those in clinical testing while for other tier categories  
177 the druggability confidence drops in order Tier 2 and then Tier 3.

178 Table 3 shows the results obtained from data on the druggable alternative genes.


179 Table 3 Druggable alternative genes

g1.name	p1.uniprot_id	p2.uniprot_id	g2.name	g2.druggability_tier
EIF2B5	Q13144	Q9P2K8	EIF2AK4	Tier 1
EIF2B5	Q13144	P49841	GSK3B	Tier 1
EIF2B5	Q13144	Q9H1Y3	OPN3	Tier 3B

### 180 3.2.2 Distinguishing vertical and horizontal pleiotropy for SNP-protein associations

181 A key MR assumption is that the genetic variant (SNP) is only related to the outcome of interest  
182 through the exposure under study (the “exclusion restriction” assumption). This assumption is  
183 potentially violated under horizontal pleiotropy, where a SNP is associated with multiple phenotypes  
184 (e.g. proteins) independently of the exposure of interest. In contrast, vertical pleiotropy, where a SNP  
185 is associated with multiple phenotypes on the causal pathway to the outcome, does not violate the  
186 “exclusion restriction criterion” of MR.

187 Here, by integrating SNP-protein associations with biological pathway and protein-protein  
188 interaction (PPI) information retrieved from EpiGraphDB, we have developed an approach to assess  
189 potential horizontal pleiotropy. For a SNP associated with a group of proteins, we check the number  
190 of biological pathways and PPIs that are shared across this group of proteins. If these proteins are  
191 mapped to the same biological pathway and/or a PPI exists between them, then the SNP is more  
192 likely to act through vertical pleiotropy and therefore be a valid instrument for MR.



193

194 Figure 2 pathway\_protein\_graph

195 From the graph above we can see that P49841 and Q9P2K8 have same biological pathways, the table  
196 below illustrates the specific pathways that how they interact.


197 Table 4 Specific pathways that how proteins interact

node.name	node.id	node.url
Cellular responses to external stimuli	R-HSA-8953897	<a href="https://reactome.org/PathwayBrowser/#/R-HSA-8953897">https://reactome.org/PathwayBrowser/#/R-HSA-8953897</a>
Cellular responses to stress	R-HSA-2262752	<a href="https://reactome.org/PathwayBrowser/#/R-HSA-2262752">https://reactome.org/PathwayBrowser/#/R-HSA-2262752</a>

198 Then we complement the information given by pathway ontologies with data of interactions between  
199 proteins. For each pair of proteins, we retrieve shared protein-protein interactions, either a direct



200 interaction or an interaction where there's one mediator protein in the middle. As can be seen from  
201 the figure3, for each pair of proteins, there are shared protein-protein interactions.



202


203

Figure 3 ppi\_protein\_graph

204 Overall, these results indicate that our study will not violate under horizontal pleiotropy.

### 205 3.2.3 Using Mendelian randomization results for causal effect estimation


206 The next step is to find out whether any of these genes have a comparable and statistically plausible  
207 effect on BD. For further analysis we select the gene of interest (EIF2B5) as well as its interacting  
208 genes with Tier 1 druggability.



209

210


Figure 4 Scatter plots of the association of EIF2B5 and BD



211

212

Figure 5 Scatter plots of the association of EIF2AK4 and BD



213

214

Figure 6 Scatter plots of the association of GSK3B and BD

215 It is worth noting that there were also differences in the ratios of MR test. According to Burgess et al.  
216 (2023); Burgess and Thompson (2017), due to the heterogeneity test highlighting the existence of  
217 heterogeneity ( $P < 0.05$ ), we give priority to using a random effect model of IVW and/or Weighted  
218 median method. The results, as shown in Table 5, indicate that a causal association was found  
219 between EIF2B5, EIF2AK4, GSK3B and BD.

It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/).

Table 5 MR analysis of putative causal BD genes and bipolar disorder.

exposure	outcome	method	nntp	b	se	MR analyses										Heterogeneity				Pleiotropy	
						pval	lo_ci	up_ci	or	or_lo95	or_uc95	Q	Q_df	Q_pval	egger_intercept	se	pval				
<i>EIF2B5</i> ( <i>clump_r2</i> =0.18, <i>clump_kb</i> =1000)	BD	MIR Egger	65	-5.21E-01	1.20E+00	6.65E-01	-2.87E+00	1.82E+00	5.94E-01	5.69E-02	6.20E+00	202058.3	63	0	3.98E-01	2.31E-01	9.08E-02				
		Weighted median	65	1.58E+00	9.13E+02	5.37E-67	1.40E+00	1.76E+00	4.85E+00	4.05E+00	5.80E+00										
	Inverse variance weighted	65	1.25E+00	6.19E-01	4.37E-02	3.54E-02	2.46E+00	3.48E+00	1.04E+00	1.17E+01	211521	64	0								
	Simple mode	65	4.25E+00	1.84E-01	8.77E-33	3.89E+00	4.61E+00	7.03E+01	4.90E+01	1.01E+02											
	Weighted mode	65	1.50E+00	2.45E-01	6.76E-08	1.02E+00	1.98E+00	4.47E+00	2.76E+00	7.23E+00											
	MIR Egger	290	1.72E+00	6.70E-01	1.09E-02	4.04E-01	3.03E+00	5.57E+00	1.50E+00	2.07E+01	1570106	288	0	-1.54E-01	1.15E-01	1.81E-01					
	Weighted median	290	2.31E+00	6.09E-02	0.00E+00	2.19E+00	2.43E+00	1.00E+01	8.92E+00	1.13E+01											
	Inverse variance weighted	290	9.42E-01	3.39E-01	5.46E-03	2.77E-01	1.61E+00	2.57E+00	1.32E+00	4.99E+00	1579904	289	0								
	Simple mode	290	5.59E+00	8.68E-02	2.37E-173	5.41E+00	5.76E+00	2.66E+02	2.25E+02	3.16E+02											
	Weighted mode	290	3.19E+00	8.52E-02	7.01E-113	3.02E+00	3.36E+00	2.43E+01	2.05E+01	2.87E+01											
<i>GSK3B</i> ( <i>clump_r2</i> =0.05, <i>clump_kb</i> =100)	MIR Egger	19	-4.98E-01	2.78E+00	8.60E-01	-5.95E+00	4.95E+00	6.08E-01	2.62E-03	1.41E+02	37775.24	17	0	5.82E-01	4.31E-01	1.95E-01					
	Weighted median	19	1.81E+00	1.21E-01	1.70E-50	1.57E+00	2.04E+00	6.09E+00	4.81E+00	7.72E+00											
	Inverse variance weighted	19	2.80E+00	1.36E+00	3.93E-02	1.38E-01	5.46E+00	1.64E+01	1.15E+00	2.35E+02	41822.66	18	0								
	Simple mode	19	5.59E+00	4.32E-01	1.50E-10	4.74E+00	6.44E+00	2.68E+02	1.15E+02	6.25E+02											
	Weighted mode	19	2.16E+00	1.07E-01	8.31E-14	1.95E+00	2.36E+00	8.63E+00	7.00E+00	1.06E+01											

## 221 4 Discussion

222 The results of this study show that EIF2B5 is the potential disease-causing gene of BD, EIF2AK4  
223 and GSK3B may become alternative drug targets for this disease.

224 Perhaps the most interesting finding is early research regarding EIF2B5 mainly aimed to study the  
225 roles of its expression in few cancerous tissue(Hou et al., 2020; Jiao et al., 2018; Xue et al., 2014;  
226 Yang et al., 2014), multiple sclerosis(Zahoor et al., 2017), and vanishing white matter (VWM)  
227 (Dietrich et al., 2005)syndrome. Importantly, the eIF2B complex plays a central role in the cellular  
228 integrated stress response (ISR). Stress-dependent kinase activation leads to phosphorylation of eIF2,  
229 which binds eIF2B more tightly and reduces overall protein synthesis. Previous research has  
230 established that white matter microstructure alterations in bipolar disorder(Adler et al., 2004; Bellani  
231 & Brambilla, 2011; Bellani et al., 2012; López-Larson et al., 2002; Yurgelun-Todd et al., 2007).  
232 However, eukaryotic translation initiation factor 2B (EIF2B) gene family encoding the five subunits  
233 of eIF2B complex- $\alpha$ ,  $\beta$ ,  $\gamma$ ,  $\delta$  and  $\epsilon$  respectively. This finding supports previous research into this brain  
234 area which links EIF2B5 and BD.

235 The ISR responds to a variety of different stress conditions that lead to alterations in cellular  
236 homeostasis. In metazoans, these stresses are sensed by at least four different kinases that each  
237 phosphorylate Ser51 in eIF2a to activate the ISR(Wek, 2018). One of them, GCN2(gene name  
238 EIF2AK4) contains a regulatory domain homologous with histidyl-tRNA synthetase and when amino  
239 acids are scarce, binding of deacylated His-tRNA triggers its activation (Harding et al., 2000;  
240 Hinnebusch, 2005). However, the precise mechanism(s) underlying these vastly different activation  
241 modalities remain unknown. But it is well known that the HPA axis is closely related to stress and  
242 AgRP neurons(Cleber Gama de Barcellos Filho et al., 2021; Perry et al., 2015; Perry et al., 2019). A  
243 possible explanation for this might further support the idea of Yuan et al. (2023): hypothalamic  
244 AgRP neurons are involved in the process of leucine deficiency improving depressive-like behavior  
245 induced by CRS, and the amino acid sensor general control non-derepressible 2 (GCN2) mediates  
246 this behavioral effect of AgRP neurons.

247 When it comes to GSK3B, Chen et al. (2014) showed that published data on the association between  
248 GSK3B -50C/T (rs334558) and bipolar disorder are inconclusive. This differs from the findings  
249 presented here. It could be argued that the positive results were due to the relatively much bigger  
250 sample size and a multiple SNPs-based approach can provide a more objective evaluation. Despite its  
251 exploratory nature, this study offers some insight into GSK3B, which is not only implicated in the  
252 pathophysiology of Alzheimer disease (Mendes et al., 2009), Parkinson disease (Wider et al., 2011),  
253 schizophrenia (Chen et al., 2020), and depressive disorders (Levchenko et al., 2018).

254 The generalisability of these results is subject to certain limitations. Firstly, the SMR method cannot  
255 distinguish pleiotropic genes from the causative genes. The association between prioritized genes and  
256 BD needs to be validated by follow-up functional studies. Moreover, BD cohorts in our data were  
257 collected in Europe, North America and Australia, so these findings cannot be extrapolated to all  
258 patients.

## 259 5 Conclusion

260 This study set out to examine the relationship between ISR and BD, also, assess the feasibility of  
261 some genes' druggability. The most obvious finding to emerge from this study is that we established  
262 causal relationships between genetic variants, candidate genes, and BD risk. The insights gained from  
263 this study may be of assistance to cure this disease.

## 264 **6 Conflict of Interest**

265 *The authors declare that the research was conducted in the absence of any commercial or financial*  
266 *relationships that could be construed as a potential conflict of interest.*

## 267 **7 Author Contributions**

268 ZT designed this study, analyzed data, and wrote the draft of the manuscript. Prof.Deng huihua  
269 discussed and reviewed the manuscript critically. All authors contributed to the article and approved  
270 the submitted version.

## 271 **8 Acknowledgments**

272 The authors thank Yang Lab for the user-friendly SMR software. We also appreciate consortia such  
273 as the PGC, GTEx and eQTLGen for providing publicly available data.

## 274 **9 Data Availability Statement**

275 The summary-level data of the GWAS on BD was publicly available from the Psychiatric Genomics  
276 Consortium ([https://figshare.com/articles/dataset/bip2021\\_noUKBB/22564402/1](https://figshare.com/articles/dataset/bip2021_noUKBB/22564402/1)). The eQTL dataset  
277 was publicly available from the eQTLGen consortium (<https://www.eqtlgen.org/>). V8 release of the  
278 GTEx eQTL/sQTL summary data can be downloaded from  
279 <https://yanglab.westlake.edu.cn/software/smr/#DataResource>.

## 280 **10 Reference**

- 281 Adler, C. M., Holland, S. K., Schmithorst, V., Wilke, M., Weiss, K. L., Pan, H., & Strakowski, S. M.  
282 (2004). Abnormal frontal white matter tracts in bipolar disorder: a diffusion tensor imaging  
283 study. *Bipolar Disorders*, 6(3), 197-203. <https://doi.org/10.1111/j.1399-5618.2004.00108.x>
- 284 Atkin, J. D., Farg, M. A., Walker, A. K., McLean, C., Tomas, D., & Horne, M. K. (2008).  
285 Endoplasmic reticulum stress and induction of the unfolded protein response in human  
286 sporadic amyotrophic lateral sclerosis. *Neurobiology of Disease*, 30(3), 400-407.  
287 <https://doi.org/10.1016/j.nbd.2008.02.009>
- 288 Bellani, M., & Brambilla, P. (2011). Diffusion imaging studies of white matter integrity in bipolar  
289 disorder. *Epidemiology and Psychiatric Sciences*, 20(2), 137-140.  
290 <https://doi.org/10.1017/s2045796011000229>
- 291 Bellani, M., Perlini, C., Ferro, A., Cerruti, S., Rambaldelli, G., Isola, M., Cerini, R., Dusi, N.,  
292 Andreone, N., Balestrieri, M., Mucelli, R. P., Tansella, M., & Brambilla, P. (2012). White  
293 matter microstructure alterations in bipolar disorder. *Functional Neurology*, 27(1), 29-34.  
294 <https://pubmed.ncbi.nlm.nih.gov/22687164/>
- 295 Buffington, S. A., Huang, W., & Costa-Mattioli, M. (2014). Translational Control in Synaptic  
296 Plasticity and Cognitive Dysfunction. In S. E. Hyman (Ed.), *Annual Review of Neuroscience*,  
297 Vol 37 (Vol. 37, pp. 17-38). Annual Reviews. <https://doi.org/10.1146/annurev-neuro-071013-014100>
- 299 Burgess, S., Davey Smith, G., Davies, N., Dudbridge, F., Gill, D., Glymour, M., Hartwig, F., Kutalik,  
300 Z., Holmes, M., Minelli, C., Morrison, J., Pan, W., Relton, C., & Theodoratou, E. (2023).  
301 Guidelines for performing Mendelian randomization investigations: update for summer 2023

- 302 [version 3; peer review: 2 approved]. *Wellcome Open Research*, 4(186).  
303 <https://doi.org/10.12688/wellcomeopenres.15555.3>
- 304 Burgess, S., & Thompson, S. G. (2017). Interpreting findings from Mendelian randomization using  
305 the MR-Egger method. *European Journal of Epidemiology*, 32(5), 377-389.  
306 <https://doi.org/10.1007/s10654-017-0255-x>
- 307 Chang, R. C. C., Wong, A. K. Y., Ng, H.-K., & Hugon, J. (2002). Phosphorylation of eukaryotic  
308 initiation factor-2 $\alpha$  (eIF2 $\alpha$ ) is associated with neuronal degeneration in Alzheimer's disease.  
309 *NeuroReport*, 13(18), 2429-2432. <https://doi.org/10.1097/00001756-200212200-00011>
- 310 Chen, G. D., Tang, J., Yu, G. W., Chen, Y. P., Wang, L. C., & Zhang, Y. (2014). Meta-analysis  
311 demonstrates lack of association of the <i>GSK3B</i>-50C/T polymorphism with risk of  
312 bipolar disorder. *Molecular Biology Reports*, 41(9), 5711-5718.  
313 <https://doi.org/10.1007/s11033-014-3441-x>
- 314 Chen, Y., Hua, S., Wang, W. P., Fan, W. X., Tang, W., Zhang, Y., & Zhang, C. (2020). A  
315 comprehensive analysis of <i>GSK3B</i> variation for schizophrenia in Han Chinese  
316 individuals. *Asian Journal of Psychiatry*, 47, Article 101832.  
317 <https://doi.org/10.1016/j.ajp.2019.10.012>
- 318 Chou, A., Krukowski, K., Jopson, T., Zhu, P. J., Costa-Mattioli, M., Walter, P., & Rosi, S. (2017).  
319 Inhibition of the integrated stress response reverses cognitive deficits after traumatic brain  
320 injury. *Proceedings of the National Academy of Sciences of the United States of America*,  
321 114(31), E6420-E6426. <https://doi.org/10.1073/pnas.1707661114>
- 322 Cleber Gama de Barcellos Filho, P., Campos Zanelatto, L., Amélia Aparecida Santana, B., Calado,  
323 R. T., & Rodrigues Franci, C. (2021). Effects chronic administration of corticosterone and  
324 estrogen on HPA axis activity and telomere length in brain areas of female rats. *Brain*  
325 *Research*, 1750, 147152. <https://doi.org/10.1016/j.brainres.2020.147152>
- 326 Consortium, T. G., Aguet, F., Anand, S., Ardlie, K. G., Gabriel, S., Getz, G. A., Graubert, A.,  
327 Hadley, K., Handsaker, R. E., Huang, K. H., Kashin, S., Li, X., MacArthur, D. G., Meier, S.  
328 R., Nedzel, J. L., Nguyen, D. T., Segrè, A. V., Todres, E., Balliu, B., . . . Volpi, S. (2020).  
329 The GTEx Consortium atlas of genetic regulatory effects across human tissues. *Science*,  
330 369(6509), 1318-1330. <https://doi.org/10.1126/science.aaz1776>
- 331 Costa-Mattioli, M., & Walter, P. (2020). The integrated stress response: From mechanism to disease.  
332 *Science*, 368(6489), 384+, Article eaat5314. <https://doi.org/10.1126/science.aat5314>
- 333 de Kloet, E. R., Joëls, M., & Holsboer, F. (2005). Stress and the brain:: From adaptation to disease.  
334 *Nature Reviews Neuroscience*, 6(6), 463-475. <https://doi.org/10.1038/nrn1683>
- 335 de Kloet, E. R., Sibug, R. M., Helmerhorst, F. M., & Schmidt, M. (2005). Stress, genes and the  
336 mechanism of programming the brain for later life. *Neuroscience and Biobehavioral Reviews*,  
337 29(2), 271-281. <https://doi.org/10.1016/j.neubiorev.2004.10.008>
- 338 *Diagnostic and statistical manual of mental disorders: DSM-5™, 5th ed.* (2013). American  
339 Psychiatric Publishing, Inc. <https://doi.org/10.1176/appi.books.9780890425596>
- 340 Dietrich, J., Lacagnina, M., Gass, D., Richfield, E., Mayer-Pröschel, M., Noble, M., Torres, C., &  
341 Pröschel, C. (2005). <i>EIF2B5</i> mutations compromise GFAP<sub>+</sub> astrocyte  
342 generation in vanishing white matter leukodystrophy. *Nature Medicine*, 11(3), 277-283.  
343 <https://doi.org/10.1038/nm1195>



- 344 Emdin, C. A., Khera, A. V., & Kathiresan, S. (2017). Mendelian Randomization. *JAMA*, *318*(19),  
345 1925-1926. <https://doi.org/10.1001/jama.2017.17219>
- 346 Finan, C., Gaulton, A., Kruger, F. A., Lumbers, R. T., Shah, T., Engmann, J., Galver, L., Kelley, R.,  
347 Karlsson, A., Santos, R., Overington, J. P., Hingorani, A. D., & Casas, J. P. (2017). The  
348 druggable genome and support for target identification and validation in drug development.  
349 *Science Translational Medicine*, *9*(383), eaag1166.  
350 <https://doi.org/10.1126/scitranslmed.aag1166>
- 351 Giambartolomei, C., Vukcevic, D., Schadt, E. E., Franke, L., Hingorani, A. D., Wallace, C., &  
352 Plagnol, V. (2014). Bayesian Test for Colocalisation between Pairs of Genetic Association  
353 Studies Using Summary Statistics. *Plos Genetics*, *10*(5), Article e1004383.  
354 <https://doi.org/10.1371/journal.pgen.1004383>
- 355 Gold, P. W., Goodwin, F. K., & Chrousos, G. P. (1988). CLINICAL AND BIOCHEMICAL  
356 MANIFESTATIONS OF DEPRESSION .1. RELATION TO THE NEUROBIOLOGY OF  
357 STRESS. *New England Journal of Medicine*, *319*(6), 348-353.  
358 <https://doi.org/10.1056/nejm198808113190606>
- 359 Grande, I., Berk, M., Birmaher, B., & Vieta, E. (2016). Bipolar disorder [Review]. *Lancet*,  
360 *387*(10027), 1561-1572. [https://doi.org/10.1016/s0140-6736\(15\)00241-x](https://doi.org/10.1016/s0140-6736(15)00241-x)
- 361 Gu, F., Chauhan, V., & Chauhan, A. (2015). Glutathione redox imbalance in brain disorders. *Current*  
362 *Opinion in Clinical Nutrition and Metabolic Care*, *18*(1), 89-95.  
363 <https://doi.org/10.1097/mco.000000000000134>
- 364 Harding, H. P., Novoa, I., Zhang, Y., Zeng, H., Wek, R., Schapira, M., & Ron, D. (2000). Regulated  
365 Translation Initiation Controls Stress-Induced Gene Expression in Mammalian Cells.  
366 *Molecular Cell*, *6*(5), 1099-1108. [https://doi.org/10.1016/S1097-2765\(00\)00108-8](https://doi.org/10.1016/S1097-2765(00)00108-8)
- 367 Hemani, G., Zheng, J., Elsworth, B., Wade, K. H., Haberland, V., Baird, D., Laurin, C., Burgess, S.,  
368 Bowden, J., Langdon, R., Tan, V. Y., Yarmolinsky, J., Shihab, H. A., Timpson, N. J., Evans,  
369 D. M., Relton, C., Martin, R. M., Davey Smith, G., Gaunt, T. R., & Haycock, P. C. (2018).  
370 The MR-Base platform supports systematic causal inference across the human phenome.  
371 *eLife*, *7*, e34408. <https://doi.org/10.7554/eLife.34408>
- 372 Hinnebusch, A. G. (2005). TRANSLATIONAL REGULATION OF GCN4 AND THE GENERAL  
373 AMINO ACID CONTROL OF YEAST. *Annual Review of Microbiology*, *59*(1), 407-450.  
374 <https://doi.org/10.1146/annurev.micro.59.031805.133833>
- 375 Hoozemans, J. J. M., van Haastert, E. S., Eikelenboom, P., de Vos, R. A. I., Rozemuller, J. M., &  
376 Scheper, W. (2007). Activation of the unfolded protein response in Parkinson's disease.  
377 *Biochemical and Biophysical Research Communications*, *354*(3), 707-711.  
378 <https://doi.org/10.1016/j.bbrc.2007.01.043>
- 379 Hou, L., Jiao, Y., Li, Y. Q., Luo, Z. P., Zhang, X. Y., Pan, G. Q., Zhao, Y. C., Yang, Z. Y., & He, M.  
380 (2020). Low *EIF2B5* expression predicts poor prognosis in ovarian cancer. *Medicine*,  
381 *99*(5), 6, Article e18666. <https://doi.org/10.1097/md.00000000000018666>
- 382 Hwang, K. D., Bak, M. S., Kim, S. J., Rhee, S., & Lee, Y. S. (2017). Restoring synaptic plasticity  
383 and memory in mouse models of Alzheimer's disease by PKR inhibition. *Molecular Brain*,  
384 *10*, 10, Article 57. <https://doi.org/10.1186/s13041-017-0338-3>

- 385 Ishimura, R., Nagy, G., Dotu, I., Chuang, J. H., & Ackerman, S. L. (2016). Activation of GCN2  
386 kinase by ribosome stalling links translation elongation with translation initiation. *eLife*, 5, 22,  
387 Article e14295. <https://doi.org/10.7554/eLife.14295>
- 388 Jiao, Y., Fu, Z., Li, Y. Q., Meng, L. Y., & Liu, Y. H. (2018). High EIF2B5 mRNA expression and its  
389 prognostic significance in liver cancer: a study based on the TCGA and GEO database.  
390 *Cancer Management and Research*, 10, 6003-6014. <https://doi.org/10.2147/cmar.S185459>
- 391 Kanner, A. M. (2012). Can neurobiological pathogenic mechanisms of depression facilitate the  
392 development of seizure disorders? *Lancet Neurology*, 11(12), 1093-1102.  
393 [https://doi.org/10.1016/s1474-4422\(12\)70201-6](https://doi.org/10.1016/s1474-4422(12)70201-6)
- 394 Kulak, A., Steullet, P., Cabungcal, J. H., Werge, T., Ingason, A., Cuenod, M., & Do, K. Q. (2013).  
395 Redox Dysregulation in the Pathophysiology of Schizophrenia and Bipolar Disorder: Insights  
396 from Animal Models. *Antioxidants & Redox Signaling*, 18(12), 1428-1443.  
397 <https://doi.org/10.1089/ars.2012.4858>
- 398 Lackovic, M., Rovcanin, B., Pantovic, M., Ivkovic, M., Petronijevic, N., & Damjanovic, A. (2013).  
399 ASSOCIATION OF OXIDATIVE STRESS WITH THE PATHOPHYSIOLOGY OF  
400 DEPRESSION AND BIPOLAR DISORDER. *Archives of Biological Sciences*, 65(1), 369-  
401 373. <https://doi.org/10.2298/abs1301369l>
- 402 Leboyer, M., Soreca, I., Scott, J., Frye, M., Henry, C., Tamouza, R., & Kupfer, D. J. (2012). Can  
403 bipolar disorder be viewed as a multi-system inflammatory disease? *Journal of Affective*  
404 *Disorders*, 141(1), 1-10. <https://doi.org/10.1016/j.jad.2011.12.049>
- 405 Levchenko, A., Losenkov, I. S., Vyalova, N. M., Simutkin, G. G., Bokhan, N. A., Wilffert, B.,  
406 Loonen, A. J. M., & Ivanova, S. A. (2018). The functional variant rs334558 of GSK3B is  
407 associated with remission in patients with depressive disorders. *Pharmacogenomics &*  
408 *Personalized Medicine*, 11, 121-126. <https://doi.org/10.2147/pgpm.S171423>
- 409 Liu, Y., Elsworth, B., Erola, P., Haberland, V., Hemani, G., Lyon, M., Zheng, J., Lloyd, O.,  
410 Vabistsevits, M., & Gaunt, T. R. (2020). EpiGraphDB: a database and data mining platform  
411 for health data science. *Bioinformatics*, 37(9), 1304-1311.  
412 <https://doi.org/10.1093/bioinformatics/btaa961>
- 413 López-Larson, M. P., DelBello, M. P., Zimmerman, M. E., Schwiers, M. L., & Strakowski, S. M.  
414 (2002). Regional prefrontal gray and white matter abnormalities in bipolar disorder.  
415 *Biological Psychiatry*, 52(2), 93-100, Article Pii s0006-3223(02)01350-1.  
416 [https://doi.org/10.1016/s0006-3223\(02\)01350-1](https://doi.org/10.1016/s0006-3223(02)01350-1)
- 417 Mayer, F. L., Sánchez-León, E., & Kronstad, J. W. (2018). A chemical genetic screen reveals a role  
418 for proteostasis in capsule and biofilm formation by *Cryptococcus neoformans*.  
419 *Microbial Cell*, 5(11), 495-510. <https://doi.org/10.15698/mic2018.11.656>
- 420 Mendes, C. T., Mury, F. B., Moreira, E. D., Alberto, F. L., Forlenza, O. V., Dias-Neto, E., & Gattaz,  
421 W. F. (2009). Lithium reduces Gsk3b mRNA levels: implications for Alzheimer Disease.  
422 *European Archives of Psychiatry and Clinical Neuroscience*, 259(1), 16-22.  
423 <https://doi.org/10.1007/s00406-008-0828-5>
- 424 Moon, S. L., Sonenberg, N., & Parker, R. (2018). Neuronal Regulation of eIF2 $\alpha$  Function in Health  
425 and Neurological Disorders. *Trends in Molecular Medicine*, 24(6), 575-589.  
426 <https://doi.org/10.1016/j.molmed.2018.04.001>

- 427 Perry, R. J., Lee, S., Ma, L., Zhang, D., Schlessinger, J., & Shulman, G. I. (2015). FGF1 and FGF19  
428 reverse diabetes by suppression of the hypothalamic–pituitary–adrenal axis. *Nature*  
429 *communications*, 6(1), 6980. <https://doi.org/10.1038/ncomms7980>
- 430 Perry, R. J., Resch, J. M., Douglass, A. M., Madara, J. C., Rabin-Court, A., Kucukdereli, H., Wu, C.,  
431 Song, J. D., Lowell, B. B., & Shulman, G. I. (2019). Leptin’s hunger-suppressing effects are  
432 mediated by the hypothalamic–pituitary–adrenocortical axis in rodents. *Proceedings of the*  
433 *National Academy of Sciences*, 116(27), 13670-13679.  
434 <https://doi.org/doi:10.1073/pnas.1901795116>
- 435 Prusty, B. K., Gulve, N., Govind, S., Krueger, G. R. F., Feichtinger, J., Larcombe, L., Aspinall, R.,  
436 Ablashi, D. V., & Toro, C. T. (2018). Active HHV-6 Infection of Cerebellar Purkinje Cells in  
437 Mood Disorders. *Frontiers in Microbiology*, 9, Article 1955.  
438 <https://doi.org/10.3389/fmicb.2018.01955>
- 439 Rosenblat, J. D., & McIntyre, R. S. (2015). Are medical comorbid conditions of bipolar disorder due  
440 to immune dysfunction? *Acta Psychiatrica Scandinavica*, 132(3), 180-191.  
441 <https://doi.org/10.1111/acps.12414>
- 442 Rowland, T. A., & Marwaha, S. (2018). Epidemiology and risk factors for bipolar disorder.  
443 *Therapeutic Advances in Psychopharmacology*, 8(9), 251-269.  
444 <https://doi.org/10.1177/2045125318769235>
- 445 Sen, T., Gupta, R., Kaiser, H., & Sen, N. (2017). Activation of PERK Elicits Memory Impairment  
446 through Inactivation of CREB and Downregulation of PSD95 After Traumatic Brain Injury.  
447 *Journal of Neuroscience*, 37(24), 5900-5911. <https://doi.org/10.1523/jneurosci.2343-16.2017>
- 448 Smith, H. L., & Mallucci, G. R. (2016). The unfolded protein response: mechanisms and therapy of  
449 neurodegeneration. *Brain*, 139, 2113-2121. <https://doi.org/10.1093/brain/aww101>
- 450 Sullivan, P. (2023). *bip2021\_noUKBB.figshare*. <https://doi.org/10.6084/m9.figshare.22564402.v1>
- 451 Tible, M., Liger, F. M., Schmitt, J., Giralt, A., Farid, K., Thomasseau, S., Gourmaud, S., Paquet, C.,  
452 Reig, L. R., Meurs, E., Girault, J. A., & Hugon, J. (2019). PKR knockout in the 5xFAD  
453 model of Alzheimer's disease reveals beneficial effects on spatial memory and brain lesions.  
454 *Aging Cell*, 18(3), 11, Article e12887. <https://doi.org/10.1111/accel.12887>
- 455 Vieta, E., Salagre, E., Grande, I., Carvalho, A. F., Fernandes, B. S., Berk, M., Birmaher, B., Tohen,  
456 M., & Suppes, T. (2018). Early Intervention in Bipolar Disorder. *American Journal of*  
457 *Psychiatry*, 175(5), 411-426. <https://doi.org/10.1176/appi.ajp.2017.17090972>
- 458 Vösa, U., Claringbould, A., Westra, H.-J., Bonder, M. J., Deelen, P., Zeng, B., Kirsten, H., Saha, A.,  
459 Kreuzhuber, R., Yazar, S., Brugge, H., Oelen, R., de Vries, D. H., van der Wijst, M. G. P.,  
460 Kasela, S., Pervjakova, N., Alves, I., Favé, M.-J., Agbessi, M., . . . i, Q. T. L. C. (2021).  
461 Large-scale cis- and trans-eQTL analyses identify thousands of genetic loci and polygenic  
462 scores that regulate blood gene expression. *Nature Genetics*, 53(9), 1300-1310.  
463 <https://doi.org/10.1038/s41588-021-00913-z>
- 464 Wang, G., Sarkar, A., Carbonetto, P., & Stephens, M. (2020). A Simple New Approach to Variable  
465 Selection in Regression, with Application to Genetic Fine Mapping. *Journal of the Royal*  
466 *Statistical Society Series B: Statistical Methodology*, 82(5), 1273-1300.  
467 <https://doi.org/10.1111/rssb.12388>

- 468 Wek, R. C. (2018). Role of eIF2 $\alpha$  kinases in translational control and adaptation to cellular stress.  
469 *Cold Spring Harbor perspectives in biology*, 10(7), a032870.  
470 <https://doi.org/10.1101/cshperspect.a032870>
- 471 Wider, C., Vilariño-Güell, C., Heckman, M. G., Jasinska-Myga, B., Ortolaza-Soto, A. I., Diehl, N.  
472 N., Crook, J. E., Cobb, S. A., Bacon, J. A., Aasly, J. O., Gibson, J. M., Lynch, T., Uitti, R. J.,  
473 Wszolek, Z. K., Farrer, M. J., & Ross, O. A. (2011). <i>SNCA</i>, <i>MAPT</i>, and  
474 <i>GSK3B</i> in Parkinson disease: a gene-gene interaction study. *European Journal of*  
475 *Neurology*, 18(6), 876-881. <https://doi.org/10.1111/j.1468-1331.2010.03297.x>
- 476 Wu, Y., Broadaway, K. A., Raulerson, C. K., Scott, L. J., Pan, C., Ko, A., He, A., Tilford, C.,  
477 Fuchsberger, C., Locke, A. E., Stringham, H. M., Jackson, A. U., Narisu, N., Kuusisto, J.,  
478 Pajukanta, P., Collins, F. S., Boehnke, M., Laakso, M., Lusi, A. J., . . . Mohlke, K. L. (2019).  
479 Colocalization of GWAS and eQTL signals at loci with multiple signals identifies additional  
480 candidate genes for body fat distribution. *Human Molecular Genetics*, 28(24), 4161-4172.  
481 <https://doi.org/10.1093/hmg/ddz263>
- 482 Xue, D., Lu, M., Gao, B., Qiao, X., & Zhang, Y. (2014). Screening for transcription factors and their  
483 regulatory small molecules involved in regulating the functions of CL1-5 cancer cells under  
484 the effects of macrophage-conditioned medium. *Oncol Rep*, 31(3), 1323-1333.  
485 <https://doi.org/10.3892/or.2013.2937>
- 486 Yang, S., Zhang, H., Guo, L., Zhao, Y., & Chen, F. (2014). Reconstructing the coding and non-  
487 coding RNA regulatory networks of miRNAs and mRNAs in breast cancer. *Gene*, 548(1), 6-  
488 13. <https://doi.org/10.1016/j.gene.2014.06.010>
- 489 Yuan, F., Wu, S., Zhou, Z., Jiao, F., Yin, H., Niu, Y., Jiang, H., Chen, S., & Guo, F. (2023). Leucine  
490 deprivation results in antidepressant effects via GCN2 in AgRP neurons. *Life Metabolism*,  
491 2(1). <https://doi.org/10.1093/lifemeta/load004>
- 492 Yurgelun-Todd, D. A., Silveri, M. M., Gruber, S. A., Rohan, M. L., & Pimentel, P. J. (2007). White  
493 matter abnormalities observed in bipolar disorder: a diffusion tensor imaging study. *Bipolar*  
494 *Disorders*, 9(5), 504-512. <https://doi.org/10.1111/j.1399-5618.2007.00395.x>
- 495 Zahoor, I., Haq, E., & Asimi, R. (2017). Multiple Sclerosis and EIF2B5: A Paradox or a Missing  
496 Link. In A. A. A. Asea, F. Geraci, & P. Kaur (Eds.), *Multiple Sclerosis: Bench to Bedside: Global Perspectives on a Silent Killer* (Vol. 958, pp. 57-64). Springer International  
497 Publishing Ag. [https://doi.org/10.1007/978-3-319-47861-6\\_5](https://doi.org/10.1007/978-3-319-47861-6_5)
- 499 Zhu, Z., Zhang, F., Hu, H., Bakshi, A., Robinson, M. R., Powell, J. E., Montgomery, G. W.,  
500 Goddard, M. E., Wray, N. R., Visscher, P. M., & Yang, J. (2016). Integration of summary  
501 data from GWAS and eQTL studies predicts complex trait gene targets. *Nature Genetics*,  
502 48(5), 481-487. <https://doi.org/10.1038/ng.3538>
- 503 Zhuang, J., Li, F., Liu, X., Liu, Z. P., Lin, J. X., Ge, Y. H., Kaminski, J. M., Summers, J. B., Wang,  
504 Z. C., Ge, J., & Yu, K. M. (2009). Lithium chloride protects retinal neurocytes from nutrient  
505 deprivation by promoting DNA non-homologous end-joining. *Biochemical and Biophysical*  
506 *Research Communications*, 380(3), 650-654. <https://doi.org/10.1016/j.bbrc.2009.01.162>

507